StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics total assets

Total assets on the balance sheet at the end of each period.

Theriva Biologics's total assets was $34.86M at Jun 30, 2026. For fiscal 2025 it was $38.24M, up 8.2% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $71.86M in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$38.24M+8.2%
FY2024Dec 31, 2024$35.35M-36.0%
FY2023Dec 31, 2023$55.22M-23.2%
FY2022Dec 31, 2022$71.86M+2.1%
FY2021Dec 31, 2021$70.37M+736.7%
FY2020Dec 31, 2020$8.41M-51.2%
FY2019Dec 31, 2019$17.24M-42.8%
FY2018Dec 31, 2018$30.14M+60.0%
FY2017Dec 31, 2017$18.84M-16.3%
FY2016Dec 31, 2016$22.50M-27.1%
FY2015Dec 31, 2015$30.85M+61.1%
FY2014Dec 31, 2014$19.14M+17.8%
FY2013Dec 31, 2013$16.26M+21.1%
FY2012Dec 31, 2012$13.42M+79.5%
FY2011Dec 31, 2011$7.48M+81.9%
FY2010Dec 31, 2010$4.11M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$34.86M-2.7%
Q1 FY2026Mar 31, 2026$38.25M+18.9%
Q4 FY2025Dec 31, 2025$38.24M+8.2%
Q3 FY2025Sep 30, 2025$30.84M-23.1%
Q2 FY2025Jun 30, 2025$35.83M-15.5%
Q1 FY2025Mar 31, 2025$32.16M-34.0%
Q4 FY2024Dec 31, 2024$35.35M-36.0%
Q3 FY2024Sep 30, 2024$40.11M-34.8%
Q2 FY2024Jun 30, 2024$42.39M-35.2%
Q1 FY2024Mar 31, 2024$48.73M-28.2%
Q4 FY2023Dec 31, 2023$55.22M-23.2%
Q3 FY2023Sep 30, 2023$61.55M-20.2%
Q2 FY2023Jun 30, 2023$65.45M-18.8%
Q1 FY2023Mar 31, 2023$67.89M-23.7%
Q4 FY2022Dec 31, 2022$71.86M+2.1%
Q3 FY2022Sep 30, 2022$77.11M+2.7%
Q2 FY2022Jun 30, 2022$80.64M+4.4%
Q1 FY2022Mar 31, 2022$89.00M+12.6%
Q4 FY2021Dec 31, 2021$70.37M+736.7%
Q3 FY2021Sep 30, 2021$75.12M+942.9%
Q2 FY2021Jun 30, 2021$77.26M+706.3%
Q1 FY2021Mar 31, 2021$79.05M+565.0%
Q4 FY2020Dec 31, 2020$8.41M-51.2%
Q3 FY2020Sep 30, 2020$7.20M-65.3%
Q2 FY2020Jun 30, 2020$9.58M-60.1%
Q1 FY2020Mar 31, 2020$11.89M-55.4%
Q4 FY2019Dec 31, 2019$17.24M-42.8%
Q3 FY2019Sep 30, 2019$20.74M+92.1%
Q2 FY2019Jun 30, 2019$24.00M+185.1%
Q1 FY2019Mar 31, 2019$26.63M+113.6%
Q4 FY2018Dec 31, 2018$30.14M+60.0%
Q3 FY2018Sep 30, 2018$10.80M-53.6%
Q2 FY2018Jun 30, 2018$8.42M-46.5%
Q1 FY2018Mar 31, 2018$12.47M-29.6%
Q4 FY2017Dec 31, 2017$18.84M-16.3%
Q3 FY2017Sep 30, 2017$23.28M+182.2%
Q2 FY2017Jun 30, 2017$15.74M–
Q1 FY2017Mar 31, 2017$17.72M–
Q4 FY2016Dec 31, 2016$22.50M–
Q3 FY2016Sep 30, 2016$8.25M–

More Theriva Biologics figures

See a number that looks wrong?